In the latest conference call, West Pharmaceutical Services Inc executives noted that although demand for GLP-1 drugs is showing strong growth momentum in 2025, the growth pace is expected to slow down in 2026.

This prediction reflects the market's professional judgment on the long-term demand curve for such metabolic disease treatment drugs, while also suggesting that the industry may be entering a period of phased adjustment. It is worth noting that the slowdown in growth does not indicate a decline in demand, but rather a natural evolution following the expansion of the market base. The underlying demand in the global diabetes and obesity treatment sector remains solid.